Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide : A randomized controlled trial of repaglinide vs sulfonylurea

Omori, Kazuno; Nomoto, Hiroshi; Nakamura, Akinobu et al.

Journal of Diabetes Investigation, 2019, 10(2), 367-374

Permalink : https://hdl.handle.net/2115/72900

このアイテムのアクセス数:815件（2026-10-10 12:25 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
jdi12889-sup-0002-tables1-3 docx 24.0 KB 194 Supporting Information: Table S1-S3
jdi12889-sup-0001-figs1 tif 103 KB 162 Supporting Information: Figure S1
Omori_et_al-2019-Journal_of_Diabetes_Investigation pdf 425 KB 540

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権
open access
URI
https://hdl.handle.net/2115/72900
タイトル
Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide : A randomized controlled trial of repaglinide vs sulfonylurea
著者
Omori, Kazuno ; Nomoto, Hiroshi ; Nakamura, Akinobu ; Takase, Takahiro ; Cho, Kyu Yong ; Ono, Kota ; Manda, Naoki ; Kurihara, Yoshio ; Aoki, Shin ; Atsumi, Tatsuya ; Miyoshi, Hideaki
著者名
Omori, Kazuno
著者名
Nomoto, Hiroshi
e-Rad_Researcher
70552420
著者名
Nakamura, Akinobu
著者名
Takase, Takahiro
著者名
Cho, Kyu Yong
著者名
Ono, Kota
著者名
Manda, Naoki
著者名
Kurihara, Yoshio
著者名
Aoki, Shin
e-Rad_Researcher
20301905
著者名
Atsumi, Tatsuya
e-Rad_Researcher
30360902
著者名
Miyoshi, Hideaki
言語
英語
キーワード
Elderly
Glucose variability
Repaglinide
発行日
2019-03
出版者
Wiley
収録物名
Journal of Diabetes Investigation
巻(号)
10(2)
ページ
367-374
抄録
Aims/Introduction: Glinides are antidiabetic drugs that enhance the early phase of insulin secretion, but have been considered to be less effective at lowering blood glucose than sulfonylureas. However, glinides show a lower risk of hypoglycemia and a greater effect on postprandial hyperglycemia, and are particularly recommended for use in elderly patients with type 2 diabetes. We investigated the efficacy and safety of repaglinide compared with sulfonylurea for the treatment of elderly patients. Materials and Methods: In the present multicenter, prospective, randomized, open-label, controlled trial, 57 elderly lean patients with type 2 diabetes who were being treated with sulfonylureas were studied. They were either switched to repaglinide (Repa group) or continued a sulfonylurea (SU group) for 12 weeks. The primary outcome comprised the change in glycemic control, and among the secondary outcomes was the presence of hypoglycemia and drug compliance. Results: Although glycated hemoglobin (HbA1c) was not significantly different between the two groups (SU +0.02% vs Repa -0.07%), greater improvements in the glycated albumin (GA) and GA to HbA1c ratio (GA/HbA1c) were observed in the Repa group (ΔGA, SU +0.12% vs Repa -1.15%; ΔGA/HbA1c, SU +0.01 vs Repa -0.13; each P < 0.01) without increasing hypoglycemia. When the Repa group was subdivided according to whether GA improved, the SU dose before switching to repaglinide was significantly smaller and the homeostatic model assessment of β-cell function was significantly higher in the GA improvement subgroup. Conclusions: Switching from SU to Repa improved GA and GA/HbA1c, and had favorable effects on glucose fluctuation in elderly patients with type 2 diabetes.
資源タイプ
学術雑誌論文
出版タイプ
Version of Record
権利情報
Creative Commons Attribution-NonCommercial 4.0 International
PISSN
2040-1116
関連情報 (isIdenticalTo)
出版社版DOI
https://doi.org/10.1111/jdi.12889